Sign in
CompletedPhase 3

A Phase 3 Study to Assess the Safety and Immunogenicity of High-dose Influenza Vaccine in Adults ≥ 60 years of Age

Key facts

Who runs it
Abbott Biologicals B.V.
Where
Belgium, Bulgaria, Estonia, Finland, and Spain44 sites in 5 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
1,283 people enrolled
Started
20 Oct 2025
Ended
4 Aug 2026
Type of study
Interventional
Record updated
31 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Willing and able to give informed consent and able to adhere to all protocol-required study procedures
  • Adults ≥ 60 years of age who are overall healthy in the clinical judgment of the investigator based on the medical history and clinical assessment (including physical examination, vital signs, clinical laboratory tests). Subjects may have underlying illnesses as long as their symptoms/signs are controlled. If on regular prescribed medication for a condition, the medication dose must have been stable for at least 3 months preceding study vaccination
  • Female subjects must be postmenopausal, defined as female subjects with at least 1 year of absence of menstruation or follicle-stimulating hormone and luteinizing hormone values of ovarian suppression
  • Ability to comply with study requirements, including the use of an application on a personal device (i.e., smartphone, tablet, etc.) or a provisioned device to record solicited events and other per-protocol required data

Who cannot take part

  • History of allergy to egg or chicken proteins, or history of any reaction or hypersensitivity to a previous dose of influenza vaccine components
  • Any concurrent condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with the evaluation of the study vaccine including (but not limited to) bleeding disorder, immunodeficiency, seizure disorder, or acute or progressive hepatic, renal, neurological, neuromuscular, or psychiatric disease
  • Receipt of any vaccine within the preceding 4 weeks of study vaccination or planned vaccination within the 4-week period following each study vaccination
  • Chronic use of systemic corticosteroids at a dose ≥ 20 mg/day of prednisone or equivalent for 14 consecutive days or more, prior to the first study vaccination or planned use thereof during the study. Topical use of corticosteroids (e.g., cream, ocular drops, inhalation and intranasal sprays), within the dosage noted on the product label, is allowed
  • Chronic systemic administration (defined as more than 14 days) of immunosuppressant or immune-modifying medication (such as monoclonal antibodies) for five elimination half-lives or the proposed time in Appendix 16.5, whichever is longer, prior to the first study vaccination or planned use thereof during the study
  • Planned administration of any influenza vaccine (other than the study vaccine) for the entire study period
  • Being a solid organ or bone marrow/stem cell transplant recipient
  • Use of cytotoxic drugs, anticancer chemotherapy, or radiation therapy within 36 months before the day of study vaccination
  • Receipt of another investigational agent within 30 days prior to study vaccination, or planned use during the entire study period
  • Known drug or alcohol abuse
  • Planned surgery requiring a general anesthetic, or planned surgery requiring inpatient hospitalization for at least 24 hours during the entire study period
  • History of serious adverse reaction to any influenza vaccine
  • History of Guillain-Barré syndrome
  • Having fever and/or acute disease or infection on the day of the first study vaccination (enrollment can be deferred for up to 2 weeks, provided the subject remains otherwise eligible). - Fever is defined as body temperature ≥ 38.0°C (measured by oral method). - Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator
  • Immunocompromising condition or immunosuppressive therapy within 6 months preceding enrollment
  • Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination
  • Laboratory confirmed influenza infection or vaccination against influenza in the 6 months preceding enrollment
  • Any other reason that, in the investigator’s opinion, prohibits the inclusion of the subject into the study
  • Receipt of blood or blood products within 3 months preceding enrollment
  • Being an employee of the Sponsor/CRO conducting this study, personnel of the study site or placed in an institution by regulatory or legal ordinance

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To demonstrate in adults ≥ 60 years of age the noninferiority of Abbott’s candidate trivalent high-dose (TIV-HD) vaccine with respect to the postvaccination hemagglutination-inhibition (HI) antibody titers compared with Efluelda® 28 days after the first vaccination.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Randomized, Observer-Blind, Active-Controlled, Phase III Study in Adults ≥ 60 years of Age to Assess the Safety and Immunogenicity of Abbott’s Candidate High-Dose Influenza Vaccine.
Record updated
31 August 2026